SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income of -$13.82M in Q1 FY2026
Q1 FY2026 net income was -$13.82M.
What to watch
Whether net income reaches the consensus estimate of -$76.01M (+90.7%) for the fiscal year ending Dec 2026.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.82M+10.1% QoQ
- Last fiscal yearDec 2025
- -$39.87M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +90.7% | — |
| 3-year CAGR | — | +43.0% | — |
| 5-year CAGR | +19.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (39.87M) USD
- Year-over-year change
- —
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.87M) | — |
Net Income vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $662.33M USD | -36.2% | +43.0% | 6.1% | |
| LTM Mar 2026 | $290.5M USD | +50.7% | +55.3% | 558.2% | |
| LTM Mar 2026 | $271.6M USD | +85.0% | +31.4% | 3566.6% | |
| LTM Jun 2026 | $188.05M USD | +102.7% | +10.5% | 30.7% | |
| LTM Jun 2026 | $167M USD | -36.5% | — | 3.1% | |
| LTM Mar 2026 | CHF 94.54M CHF | -8.3% | +34.7% | 18758.0% | |
| LTM Mar 2026 | $46.64M USD | +75.7% | -16.4% | 36.6% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $39.87M USD | — | — | — |
| LTM Mar 2026 | $37.25M USD | -24.6% | -23.6% | 46.8% | |
| LTM Apr 2026 | $21.03M USD | -70.4% | — | 7.2% | |
| Peer median (excluding SGP) | — | -8.3% | +31.4% | 36.6% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (39.87M) |
| Depreciation & Amortization | 612K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.79M |
| Change in Working Capital | 2.45M |
| Accounts Receivables | (8K) |
| Inventory | 0 |
| Accounts Payables | 549K |
| Other Working Capital | 1.91M |
| Other Non-Cash Items | 1.32M |
| Operating Cash Flow | (32.7M) |
| Capital Expenditures | (789K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (17M) |
| Sales of Investments | 6M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (11.79M) |
| Debt Repayment | 0 |
| Common Stock Issued | 170K |
| Common Stock Repurchased | (1.45M) |
| Dividends Paid | 0 |
| Other Financing Activities | (1.47M) |
| Financing Cash Flow | 124.59M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | 80.09M |
| Free Cash Flow | (33.49M) |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.